X
Archive by author: Lindsey HoughtonReturn
 Just a reminder that the revised client forms implement today! Don't forget to toss your old versions! If you need a refresher on what forms are impacted, you can read about it here: Communications  
The revised CTS algorithm associated with the Ortho platform is now available for review.  Clients receiving routine confirmatory testing will see the two new test codes when we implement the Ortho platform on January 11, 2021, the Abbott Alinity s Anti-HCV and the Genetic Systems HBsAg Confirmatory 3.0.Read all about it on the Communication page by clicking this link: Communications...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor antibody screen on the Ortho Clinical Diagnostics VISION Analyzer. This instrumentation change was necessary as Ortho Clinical Diagnostics will be discontinuing support of the existing ProVue instrumentation in the future.We will notify you of the transition date of our other four laboratories. To read more about this change, click here: 
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operations. As we get closer to our implementation date of January 11, 2021 we are committed to providing you information as it becomes available.Package inserts for the new assays are now available. You can review them on the Communications page by clicking this link: Communications
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to be a process improvement. The completion and emailing of the Daily Shipment Schedule (DSS) is an important step when sending sample shipments to CTS for testing. It is important that all necessary information is documented correctly for several reasons. The flight information and box count allow CTS to ensure the entire shipment is received and the information helps us investigate if a shipment doe...
CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.Read all about it on the Communication page by clicking this li...
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form changes to once a year when possible.  You can review the list of forms revising by clicking this link: Communications 
After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.Read all about it on the C...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA testing and has been approved by the US FDA for WNV, ZIKA, and now Ultrio Elite testing. The Procleix Panther instrument with its automated process will allow the CTS laboratories to operate with increased efficiencies with processing all three assays (WNV, ZIKA, Ultrio Elite) using a single pooled or individual donation sample. We expect less downtime and fewer NAT assay failures. On Tu...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex assay (HIV 1/2, HBV and HCV), performed on the Tigris testing platform, to the -enhanced Ultrio Elite triplex assay performed on the Panther testing platform on July 13, 2020.  The implementation date has been moved up to July 7th.  Contact your Customer Service Manager if you have any questions! 
Page 1 of 4 FirstPrevious [1]234 Last

Subscribe here to receive CTS updates!

Name